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RESULTS: Of the 230,738 eligible patients, 29.7% had depres-
sion diagnoses (n = 68,526), 71.4% were female, mean age was
44.6 years, and 77.9% initiated on SSRIs. Using logistic regres-
sion models for the depression cohort, patients initiating on
duloxetine (n = 2061) versus all other initiators were associated
with being older (OR 1.02), having more prior pain diagnoses
(OR 1.11), depression-related diagnoses (OR 1.52), major depres-
sive disorder recurrent episode diagnoses (OR 1.28), pain 
medications (OR 1.27), antidepressants (OR 1.46), and any psy-
chotherapy (OR 1.14) (all p < 0.01). Duloxetine patients also
were more likely to initiate therapy later in the study (OR 1.04;
p < 0.0001) and were prescribed therapy by mental health (OR
2.32) and other specialists (OR 1.40) versus primary care. When
depressive diagnoses were absent, duloxetine patients (n = 2346)
were more likely to be female (OR 1.21; p < 0.001) versus other
antidepressant initiators (n = 162,212). All other factors remained
consistent. Trends over time are necessary to determine the
robustness of results. CONCLUSIONS: In the ﬁrst four months
after the drug’s availability, duloxetine initiators were associated
with worse prior diagnostic and treatment histories. Case mix 
differences should be made when comparing drug cohorts.
MENTAL HEALTH—Methods and Concepts
PMH35
THE COST OF RELAPSE IN PATIENTS WITH 
SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO
(SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES)
STUDY
Zhu G1, Brown J1, Novick D1, Suarez D2, Haro JM2,Windmeijer F3
1Eli Lilly and Company Limited, Windlesham, UK, 2Sant Joan De 
Deu-SSM, Barcelona, Spain, 3University of Bristol, Bristol, UK
OBJECTIVE: To compare the treatment costs of schizophrenia
patients who relapsed in the European SOHO study with those
who never relapsed over three years. METHODS: The SOHO
study is a 3-year perspective, outpatient observational study of
10,972 patients across 10 European countries. The Clinical
Global Impression (CGI) Scale was used to measure clinical
effectiveness on a scale of 1 (not ill) to 7 (most severely ill). The
deﬁnition of relapse was based on increases in the CGI Scale
and/or inpatient admission. Kaplan-Meier analysis was used to
estimate the relapse rate over three years. The resource use (inpa-
tient, day care, psychiatrist visits and medications) for those who
ever relapsed during the three years of study was compared to
those who never relapsed. UK costs were applied to the resource
use. RESULT: A totla of 6397 patients with complete data on
CGI and resources were used in the analysis. A totla of 2489
(39%) patients relapsed over the 3 years. The total cost for
patients who relapsed (16,724.27 pounds) was higher than those
who did not relapse (7724.93 pounds). 6368.88 pounds (71%)
of cost difference was due to inpatient stays, 2020.13 pounds
was due to day-care, 416.11 pounds due to medications and
194.22 pounds due to psychiatrist visits. The costs will also be
modelled adjusting for patient characteristics and taking account
of the fact that the cost data is not normally distributed. 
CONCLUSION: Relapsed patients used more health care
resources in the treatment for schizophrenia. The cost of antipsy-
chotic treatments which prevent relapse could be offset by the
savings associated with preventing relapse.
PMH36
VARIATIONS IN THE OPERATIONAL DEFINITION OF MOOD
DISORDERS IN RETROSPECTIVE CLAIMS DATABASE STUDIES
Montejano LB
Thomson Medstat, Washington, DC, USA
OBJECTIVES: In retrospective claims database studies, deﬁning
the sample often receives less attention than the statistical
methods used in the analysis. However, identifying an appropri-
ate sample is a key step in the analytic process. The current
research was undertaken to identify typical sample selection def-
initions in retrospective claims database studies of mood disor-
ders. METHODS: A PubMed literature search was conducted to
identify January 2000 to September 2005 publications with the
major topic heading of mood disorders and terms such as admin-
istrative data, insurance claims or claims analysis. The criteria
used for sample selection was abstracted from relevant studies.
RESULTS: Forty-seven studies were abstracted, including 10
speciﬁcally focusing on major depressive disorder (MDD), 15 on
depression and 13 on bipolar disorder (BPD). No set of ICD-9-
CM diagnosis codes was used to identify these conditions across
studies. Three studies deﬁned MDD as 296.2 or 293.3 only,
while others included codes for dysthymia (300.4) and depres-
sive disorder not otherwise speciﬁed (311). Some used codes for
adjustment reaction with depressive symptoms (309.0, 309.2).
One study of depression used only 296.2 and 296.3, while
another used nine different 4-digit ICD-9 codes. All BPD studies
that speciﬁed codes used 296.4–296.6, but the inclusion of other
296 codes varied by study. Several publications did not list the
speciﬁc diagnosis codes used. Some studies required at least two
diagnoses, while others required only one. About half the studies
provided little basis for the coding criteria used. CONCLU-
SIONS: A speciﬁc operational deﬁnition of mood disorders was
not evident from the literature. Results of retrospective claims
database studies with different sample selection criteria may
vary, so it is important to assess ﬁndings in light of the sample
deﬁnition.
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OBJECTIVES: Compare adherence and persistence among
patients with bipolar disorder (BPD) initiated on quetiapine
versus other antipsychotics in a state Medicaid system over a 12-
month follow-up period. There are few published economic eval-
uations of quetiapine in comparison with other antipsychotics.
METHODS: Claims data for patients with BPD from a “de-
identiﬁed” Medicaid database. Patients were assigned to queti-
apine (QTP), olanzapine (OLZ), risperidone (RIS), or typical
antipsychotic treatment groups based on ﬁrst prescription ﬁlled
between January 1, 1999 and December 31, 2001. Adherence
was measured using the medication possession ratio (MPR):
days’ supply of antipsychotic divided by the number of days
between prescription ﬁlls. Persistence was deﬁned as total
number of days from initiation of treatment to therapy modiﬁ-
cation (discontinuation, switching, or combination with another
antipsychotic). Adjustment for confounders was undertaken
using ordinary least squares (OLS) and Cox proportional hazard
regression modeling. RESULTS: Mean (±SD) MPRs were 0.71 ±
0.25 for QTP (n = 106), 0.68 ± 0.29 for OLZ (n = 283), 0.68 ±
0.27 for RIS (n = 231), and 0.46 ± 0.34 for typical antipsychotics
(n = 205). Patients initiated on typical antipsychotics were
24.4% less adherent than patients initiated on QTP (p < 0.001).
